September 18, 2024 06:09 PM EDTUpdated 5 hours ago
Financing

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Kyle LaHucik

Senior Reporter

Just hours af­ter the US Fed­er­al Re­serve an­nounced the first in­ter­est rate cut in four years, res­pi­ra­to­ry biotech Up­stream Bio re­vealed plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Tang Cap­i­tal’s Con­cen­tra bids for Sin­gu­lar Ge­nomics days af­ter Deer­field of­fer

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times